CSL (OTCMKTS:CSLLY) Shares Gap Up – Here’s What Happened
by Mitch Edgeman · The Markets DailyShares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $59.31, but opened at $62.1750. CSL shares last traded at $61.67, with a volume of 9,368 shares changing hands.
Wall Street Analyst Weigh In
CSLLY has been the subject of a number of analyst reports. Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. Royal Bank Of Canada upgraded CSL from a “hold” rating to a “moderate buy” rating in a research report on Monday. Finally, Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, CSL presently has a consensus rating of “Buy”.
View Our Latest Stock Report on CSL
CSL Trading Up 1.5%
The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The firm’s 50-day moving average is $58.96 and its 200 day moving average is $67.87.
CSL Company Profile
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.